BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y, Hirayama R. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 2003;89:1486-1492. [PMID: 14562021 DOI: 10.1038/sj.bjc.6601335] [Cited by in Crossref: 92] [Cited by in F6Publishing: 76] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Sakurai Y, Sakamoto K, Sugimoto Y, Yoshida I, Masui T, Tonomura S, Inaba K, Shoji M, Nakamura Y, Uyama I. Orotate phosphoribosyltransferase levels measured by a newly established enzyme-linked immunosorbent assay in gastric carcinoma. Cancer Sci. 2006;97:492-498. [PMID: 16734727 DOI: 10.1111/j.1349-7006.2006.00200.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
2 Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, Endo I, Kunisaki C, Suzuki H, Hayasizaki Y, Shimada H. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three-gene expression model predicts clinical response. Int J Cancer 2006;119:406-13. [DOI: 10.1002/ijc.21843] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
3 Gusella M, Bertolaso L, Bolzonella C, Pasini F, Padrini R. Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays. Genet Test Mol Biomarkers. 2011;15:691-695. [PMID: 21631301 DOI: 10.1089/gtmb.2011.0021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
5 Ung L, Lam AK, Morris DL, Chua TC. Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. Clin Transl Oncol. 2014;16:425-435. [PMID: 24458880 DOI: 10.1007/s12094-013-1154-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
6 Naito S, Eto M, Shinohara N, Tomita Y, Fujisawa M, Namiki M, Nishikido M, Usami M, Tsukamoto T, Akaza H. Multicenter Phase II Trial of S-1 in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. JCO 2010;28:5022-9. [DOI: 10.1200/jco.2010.29.1203] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
7 Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005;5:226-243. [PMID: 16041392 DOI: 10.1038/sj.tpj.6500320] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
8 Choi IS, Lee HS, Lee KW, Kim H, Kim KH, Kim YJ, Kim JH, Kim WH, Lee JS. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med Oncol. 2011;28:991-998. [PMID: 20533001 DOI: 10.1007/s12032-010-9590-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
9 Tokunaga Y, Sasaki H, Saito T. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery. 2007;141:346-353. [PMID: 17349846 DOI: 10.1016/j.surg.2006.06.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
10 Jensen SA, Vainer B, Witton CJ, Jørgensen JT, Sørensen JB. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. Acta Oncol 2008;47:1054-61. [PMID: 18607850 DOI: 10.1080/02841860801942158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
11 Takiguchi Y, Tada Y, Gemma A, Kudoh S, Hino M, Yoshimori K, Yoshimura A, Nagao K, Niitani H. Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer. Lung Cancer 2010;68:409-14. [DOI: 10.1016/j.lungcan.2009.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
12 Nishino S, Itoh A, Matsuoka H, Maeda K, Kamoshida S. Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy. Mol Clin Oncol 2013;1:661-7. [PMID: 24649225 DOI: 10.3892/mco.2013.104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
13 Nabeya Y, Suzuki T, Furuya A, Koide N, Ohkoshi M, Takiguchi M, Ochiai T, Matsubara H, Hiwasa T. Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells. Cancer Sci. 2011;102:1509-1515. [PMID: 21561529 DOI: 10.1111/j.1349-7006.2011.01978.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
14 Nishiyama M, Eguchi H. Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv Drug Deliv Rev. 2009;61:402-407. [PMID: 19133303 DOI: 10.1016/j.addr.2008.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
15 Taomoto J, Yoshida K, Wada Y, Tanabe K, Konishi K, Tahara H, Fukushima M. Overexpression of the Orotate Phosphoribosyl-Transferase Gene Enhances the Effect of 5-Fluorouracil on Gastric Cancer Cell Lines. Oncology 2007;70:458-64. [DOI: 10.1159/000098873] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
16 Kai K, Kitajima Y, Hiraki M, Satoh S, Tanaka M, Nakafusa Y, Tokunaga O, Miyazaki K. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens. Cancer Lett 2007;258:45-54. [PMID: 17892912 DOI: 10.1016/j.canlet.2007.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
17 Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S, Ueda R. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer. 2005;49:345-351. [PMID: 15993511 DOI: 10.1016/j.lungcan.2005.05.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
18 Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Nakayama G, Ohashi N, Koike M, Yamamura Y, Nakao A. Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett. 2007;252:307-313. [PMID: 17303323 DOI: 10.1016/j.canlet.2007.01.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
19 Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H, Fukushima M. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006;95:607-15. [PMID: 16880781 DOI: 10.1038/sj.bjc.6603297] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
20 Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest 2006;24:235-41. [PMID: 16809149 DOI: 10.1080/07357900600632082] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
21 Wang T, Chen X, Li L, Cao Y, Zhao L, Chai Y, Zhu Z, Lou Z. Characterization of Nucleotides and Nucleotide Sugars in Candida albicans by High Performance Liquid Chromatography–Mass Spectrometry with a Porous Graphite Carbon Column. Analytical Letters 2013;47:234-49. [DOI: 10.1080/00032719.2013.836657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? European Journal of Cancer 2009;45:1935-49. [DOI: 10.1016/j.ejca.2009.04.023] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
23 Ishihara S, Watanabe T, Akahane T, Shimada R, Horiuchi A, Shibuya H, Hayama T, Yamada H, Nozawa K, Igaki H, Matsuda K. Prognostic significance of adverse events associated with preoperative radiotherapy for rectal cancer. Int J Colorectal Dis 2011;26:911-7. [DOI: 10.1007/s00384-011-1156-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Ijuin T, Nibu K, Doi K, Inoue H, Saitoh M, Ohtsuki N, Makino K, Amatsu M. Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer. Acta Otolaryngol. 2007;127:305-311. [PMID: 17364369 DOI: 10.1080/00016480600801381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
25 Schramm VL, Grubmeyer C. Phosphoribosyltransferase Mechanisms and Roles in Nucleic Acid Metabolism. Elsevier; 2004. pp. 261-304. [DOI: 10.1016/s0079-6603(04)78007-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
26 Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics. 2005;6:835-847. [PMID: 16296946 DOI: 10.2217/14622416.6.8.835] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
27 Matsusaka S, Lenz HJ. Pharmacogenomics of fluorouracil -based chemotherapy toxicity. Expert Opin Drug Metab Toxicol 2015;11:811-21. [PMID: 25800061 DOI: 10.1517/17425255.2015.1027684] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
28 Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y, Hirayama R. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927-1933. [PMID: 16736497 DOI: 10.1002/ijc.22080] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
29 Richard C, Duivenvoorden W, Bourbeau D, Massie B, Roa W, Yau J, Th'ng J. Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy. Cancer Gene Ther 2007;14:57-65. [PMID: 16874362 DOI: 10.1038/sj.cgt.7700980] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
30 Yano A, Shigematsu Y, Kitano H, Hanayama A, Ozawa A, Tacho T, Fujii M. Possibility of using mRNA expression levels for nucleic acid-metabolizing enzymes within prostate cancer cells as indices for prognostic factors. Oncol Lett 2010;1:1049-53. [PMID: 22870111 DOI: 10.3892/ol.2010.165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Bustin SA, Mueller R. Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer. Molecular Aspects of Medicine 2006;27:192-223. [DOI: 10.1016/j.mam.2005.12.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
32 Yanagisawa Y, Maruta F, Iinuma N, Ishizone S, Koide N, Nakayama J, Miyagawa S. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. Scand J Gastroenterol. 2007;42:477-484. [PMID: 17454858 DOI: 10.1080/00365520600994418] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
33 Li JA, Xu XF, Han X, Fang Y, Shi CY, Jin DY, Lou WH. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Pancreas. 2016;45:425-433. [PMID: 26495780 DOI: 10.1097/mpa.0000000000000501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
34 van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40:939-950. [PMID: 15093568 DOI: 10.1016/j.ejca.2003.12.004] [Cited by in Crossref: 306] [Cited by in F6Publishing: 240] [Article Influence: 18.0] [Reference Citation Analysis]
35 Miyake K, Imura S, Yoshizumi T, Ikemoto T, Morine Y, Shimada M. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. Int J Clin Oncol. 2007;12:111-119. [PMID: 17443278 DOI: 10.1007/s10147-006-0634-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
36 Jiang H, Dong Q, Luo X, Shi B, Wang H, Gao H, Kong J, Zhang J, Li Z. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Cancer Lett 2014;342:113-20. [PMID: 24007863 DOI: 10.1016/j.canlet.2013.08.038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
37 Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV. 5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Int J Cancer 2006;119:522-6. [PMID: 16572420 DOI: 10.1002/ijc.21692] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
38 Makino H, Uetake H, Danenberg K, Danenberg PV, Sugihara K. Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer. BMC Cancer 2008;8:210. [PMID: 18652704 DOI: 10.1186/1471-2407-8-210] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
39 Yoshitomi I, Kawasaki G, Yanamoto S, Mizuno A. Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the dihydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil. Oral Oncol 2006;42:880-7. [PMID: 16757204 DOI: 10.1016/j.oraloncology.2005.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
40 Shigeta K, Ishii Y, Hasegawa H, Okabayashi K, Kitagawa Y. Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. World J Surg 2014;38:3248-56. [PMID: 25167895 DOI: 10.1007/s00268-014-2738-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
41 Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, Faloppi L, Cascinu S. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 2009;35:451-62. [PMID: 19467788 DOI: 10.1016/j.ctrv.2009.04.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
42 Ichikawa W, Sasaki Y. Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients. Int J Clin Oncol 2008;13:206-11. [DOI: 10.1007/s10147-008-0786-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
43 Ichikawa W. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer. 2006;9:145-155. [PMID: 16952032 DOI: 10.1007/s10120-006-0373-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
44 Ichikawa W, Ooyama A, Toda E, Sugimoto Y, Oka T, Takahashi T, Shimizu M, Sasaki Y, Hirayama R. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin. Cancer Chemother Pharmacol 2006;58:794-801. [PMID: 16528528 DOI: 10.1007/s00280-006-0217-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
45 Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, Kurumi Y, Tani T. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 2008;61:587-94. [DOI: 10.1007/s00280-007-0511-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
46 Cao D, Ziemba A, McCabe J, Yan R, Wan L, Kim B, Gach M, Flynn S, Pizzorno G. Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity. Mol Cancer Ther 2011;10:2330-9. [PMID: 21954436 DOI: 10.1158/1535-7163.MCT-11-0202] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
47 Sadahiro S, Suzuki T, Tanaka A, Okada K, Nagase H, Uchida J. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemother Pharmacol. 2012;70:285-291. [PMID: 22752215 DOI: 10.1007/s00280-012-1909-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
48 Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20:9775-9827. [PMID: 25110414 DOI: 10.3748/wjg.v20.i29.9775] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 63] [Article Influence: 12.2] [Reference Citation Analysis]
49 Griffith M, Mwenifumbo JC, Cheung PY, Paul JE, Pugh TJ, Tang MJ, Chittaranjan S, Morin RD, Asano JK, Ally AA. Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. Pharmacogenomics J. 2013;13:148-158. [PMID: 22249354 DOI: 10.1038/tpj.2011.65] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
50 Li J, Bluth MH. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmgenomics Pers Med 2011;4:11-33. [PMID: 23226051 DOI: 10.2147/PGPM.S18861] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
51 Sakamoto E, Nagase H, Kobunai T, Oie S, Oka T, Fukushima M, Oka T. Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochemical and Biophysical Research Communications 2007;363:216-22. [DOI: 10.1016/j.bbrc.2007.08.164] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
52 Ogiuchi Y, Maruoka Y, Ando T, Kobayashi M, Ogiuchi H. Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma. Acta Histochem Cytochem 2008;41:39-46. [PMID: 18636111 DOI: 10.1267/ahc.08002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
53 Miyoshi Y, Uemura H, Ishiguro H, Kitamura H, Nomura N, Danenberg PV, Kubota Y. Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis 2005;8:260-5. [PMID: 15999119 DOI: 10.1038/sj.pcan.4500817] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
54 Shimoda M, Kubota K, Shimizu T, Katoh M. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection. Br J Surg. 2015;102:746-754. [PMID: 25833230 DOI: 10.1002/bjs.9775] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
55 Komori S, Osada S, Tomita H, Nishio K, Kumazawa I, Tachibana S, Tsuchiya J, Yoshida K. Predictive value of orotate phosphoribosyltransferase in colorectal cancer patients receiving 5-FU-based chemotherapy. Mol Clin Oncol 2013;1:453-60. [PMID: 24649191 DOI: 10.3892/mco.2013.71] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
56 Nakamura A, Nakajima G, Okuyama R, Kuramochi H, Kondoh Y, Kanemura T, Takechi T, Yamamoto M, Hayashi K. Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer 2014;17:188-95. [PMID: 23494117 DOI: 10.1007/s10120-013-0249-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
57 Wang T, Wang L, Qian X, Yu L, Ding Y, Liu B. Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites. Cancer Invest 2011;29:130-6. [PMID: 21210725 DOI: 10.3109/07357907.2010.535060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
58 Imyanitov EN, Moiseyenko VM. Molecular-based choice of cancer therapy: realities and expectations. Clin Chim Acta 2007;379:1-13. [PMID: 17306783 DOI: 10.1016/j.cca.2007.01.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
59 Ochiai T, Nishimura K, Noguchi H, Kitajima M, Tsuruoka Y, Takahashi Y, Tsukada A, Watanabe E, Nagaoka I, Futagawa S. Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy. J Surg Oncol. 2006;94:45-50. [PMID: 16788943 DOI: 10.1002/jso.20553] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
60 Huang CL, Yokomise H, Fukushima M, Kinoshita M. Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol 2006;2:289-99. [PMID: 16563096 DOI: 10.2217/14796694.2.2.289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
61 Ochiai T, Nishimura K, Noguchi H, Kitajima M, Tsukada A, Watanabe E, Nagaoka I, Futagawa S. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer. 2006;118:3084-3088. [PMID: 16425285 DOI: 10.1002/ijc.21779] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
62 Shimamoto Y, Nukatsuka M, Takechi T, Fukushima M. Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. Int J Mol Med 2016;37:319-28. [PMID: 26676887 DOI: 10.3892/ijmm.2015.2427] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
63 Akahoshi K, Ban D, Kuboki R, Oba A, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Orotate phosphoribosyltransferase as a predictor of benefit from S‐1 adjuvant chemotherapy for cholangiocarcinoma patients. Journal of Gastroenterology and Hepatology 2018;34:1108-15. [DOI: 10.1111/jgh.14477] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
64 Ishiguro M, Kotake K, Nishimura G, Tomita N, Ichikawa W, Takahashi K, Watanabe T, Furuhata T, Kondo K, Mori M. Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer. BMC Cancer. 2013;13:149. [PMID: 23530572 DOI: 10.1186/1471-2407-13-149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
65 Yoshida K, Yamaguchi K, Osada S, Kawaguchi Y, Takahashi T, Sakashita F, Tanaka Y. Challenge for a better combination with basic evidence. Int J Clin Oncol. 2008;13:212-219. [PMID: 18553230 DOI: 10.1007/s10147-008-0793-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
66 Ando T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Sugito N, Mori R, Ogawa R, Katada T, Fujii Y. Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. Dis Esophagus. 2008;21:15-20. [PMID: 18197934 DOI: 10.1111/j.1442-2050.2007.00700.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
67 Nakajima TE, Yamada Y, Shimoda T, Matsubara J, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Combination of O6-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy. Eur J Cancer. 2008;44:400-407. [PMID: 18068349 DOI: 10.1016/j.ejca.2007.11.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
68 Yasumatsu R, Nakashima T, Komune S. Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-Fluorouracil in head and neck squamous cell carcinoma in vitro. J Oncol 2012;2012:649605. [PMID: 22545049 DOI: 10.1155/2012/649605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
69 Horton JK, Tepper JE. Staging of colorectal cancer: past, present, and future. Clin Colorectal Cancer 2005;4:302-12. [PMID: 15663833 DOI: 10.3816/ccc.2005.n.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
70 Strimpakos AS, Syrigos KN, Saif MW. Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J 2009;9:147-60. [DOI: 10.1038/tpj.2009.8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
71 Che J, Pan L, Yang X, Liu Z, Huang L, Wen C, Lin A, Liu H. Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis. Mol Clin Oncol. 2017;7:943-952. [PMID: 29285354 DOI: 10.3892/mco.2017.1436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
72 Ishikawa M, Miyauchi T, Kashiwagi Y. Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy. BMC Cancer. 2008;8:188. [PMID: 18597678 DOI: 10.1186/1471-2407-8-188] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
73 Merry A, Qiao M, Hasler M, Kuwabara PE. RAD-6: pyrimidine synthesis and radiation sensitivity in Caenorhabditis elegans. Biochem J 2014;458:343-53. [PMID: 24262006 DOI: 10.1042/BJ20131085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
74 Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y, Fukushima M. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006;119:783-791. [PMID: 16557585 DOI: 10.1002/ijc.21879] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
75 Matsuda M, Shiba S, Asakawa M, Kono H, Fujii H. Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expression of fluoropyrimidine metabolism enzymes in the primary tumor. Int J Clin Oncol 2009;14:245-8. [PMID: 19593617 DOI: 10.1007/s10147-008-0820-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
76 Ackland SP, Clarke SJ, Beale P, Peters GJ. Thymidylate synthase inhibitors. Update on Cancer Therapeutics 2006;1:403-27. [DOI: 10.1016/j.uct.2006.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]